AJOONI3.49

Ajooni Biotech Limited

· Unclassified
AnnualQuarterly₹ CrorePeersTOUCHWOODRKECRAJMETBANKAAAKASHGANGAFORGEGLOBEAGROPHOSMcap ₹60.1 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations19.520.119.625.725.734.029.331.331.758.860.663.5
Other Income0.31.60.30.00.30.41.30.60.10.31.30.3
Total Income19.821.619.825.726.034.430.631.931.959.161.963.8
Expenses
+ Cost of Materials Consumed17.418.115.322.522.529.222.625.624.948.349.254.5
+ Changes in Inventories0.20.30.2-0.00.1-0.20.1-0.00.1-0.1-0.0-0.4
+ Employee Benefit Expense0.50.60.10.60.70.90.61.01.11.21.31.4
+ Finance Costs0.20.10.10.20.10.10.10.10.20.20.30.5
+ Depreciation & Amortisation0.20.20.20.20.20.20.40.20.20.80.90.8
+ Other Expenses0.71.72.41.71.73.25.04.04.16.39.26.3
Total Expenses19.221.018.325.125.233.428.730.930.656.760.863.1
EBITDA0.6-0.71.61.00.80.91.00.71.53.01.01.7
EBIT0.4-0.91.40.70.50.70.60.51.32.20.10.9
Profit
PBT before Exceptional Items0.50.61.50.60.81.01.91.01.22.41.10.7
Pretax Income0.50.61.50.60.81.01.91.01.22.41.10.7
+ Current Tax0.10.20.60.20.20.20.50.20.30.70.30.2
+ Deferred Tax-0.0-0.0-0.00.0-0.00.1-0.10.0-0.00.0-0.10.0
Tax Expense0.10.10.60.20.20.30.40.20.30.70.20.2
Net Income0.40.40.90.50.60.71.50.80.91.60.90.4
+ Net Income — Continuing Ops0.40.40.90.50.60.71.50.80.91.60.90.4
+ Other Comprehensive Income0.00.00.60.00.50.0-0.80.00.0-0.4-0.80.0
Total Comprehensive Income0.40.41.50.51.20.80.70.80.91.30.10.4
Per Share
Basic EPS0.230.250.100.030.040.040.090.020.080.100.050.01
Diluted EPS0.230.250.100.030.040.040.090.020.080.100.050.01
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.8-0.4-0.8
+ Items NOT to be Reclassified to P&L-0.8-0.8
+ Tax on Items NOT to be Reclassified0.00.40.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.230.250.100.030.040.040.090.020.080.100.050.01
Diluted EPS — Continuing Operations0.230.250.100.030.040.040.090.020.080.100.050.01
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period1.31.50.9
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1.91.64.13.23.25.06.65.76.710.611.59.3
Gross Margin %9.668.0720.9312.4312.2814.8022.4618.1321.2317.9918.9314.70
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)0.50.61.50.60.81.01.91.01.22.41.10.7
Net Income Adj (tax-effected)0.40.40.90.50.60.71.50.80.91.60.90.4
EPS Adj0.230.250.100.030.040.040.090.020.080.100.050.01
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.005,441.162.002.002.002.00
Paid Up Equity Capital17.517.517.534.434.434.434.434.434.434.434.434.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.